Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study

By Blockeel C.   De Vos M.   Verpoest W.   Stoop D.   Haentjens P.   Devroey P.  

Human Reproduction, Vol. 24, Iss. 11, 2009-11 ,pp. : 2910-2916

Oxford University Press

Access to resources Recommend Favorite

Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study

By Ludwig M.  

Human Reproduction, Vol. 17, Iss. 11, 2002-11 ,pp. : 2842-2845

Oxford University Press

Access to resources Recommend Favorite

Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study

By Cédrin-Durnerin I.  

Human Reproduction, Vol. 19, Iss. 9, 2004-09 ,pp. : 1979-1984

Oxford University Press

Access to resources Recommend Favorite

The administration of the GnRH antagonist, cetrorelix, to ooctye donors simplifies oocyte donation

By Thong K.J.  

Human Reproduction, Vol. 18, Iss. 6, 2003-06 ,pp. : 1256-1258

Oxford University Press

Access to resources Recommend Favorite

Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes

By Papanikolaou Evangelos G.   Bourgain Claire   Kolibianakis Efstratios   Tournaye Herman   Devroey Paul  

Human Reproduction, Vol. 20, Iss. 6, 2005-06 ,pp. : 1541-1547

Oxford University Press

Access to resources Recommend Favorite